CB Insights：2026年Q1全球数字医疗行业现状报告：全球私募市场数字医疗企业的交易、融资及退出数据与分析（英文版）（106页）.pdf

1、State of Digital HealthGlobal|Q1 2026Global data and analysis on dealmaking,funding,and exits by private market digital health companies 2026 CB Insights|2Insights are good.Action is better.We track and compare the worlds companies.Our AI agents keep you a step ahead of competitors and disruption.Tr

2、usted by the worlds smartest companies:Every big tech company.Every top professional services firm.26 of the top 30 banks.All ten Fortune 10 companies.Put our AI agents to work today.IIIIIIStart free trial 2026 CB Insights|3Go Deeper.All the data behind this report is live on the CB Insights platfor

3、m.Filter it,download it,build your own analysis.IIIIIIExplore the dataTL;DR 2026 CB Insights|4Your rundown ondigital health in Q126$7.4BHighest global funding since Q222.Quarterly funding hit$7.4B,a 25%QoQ increase from Q425,but gains are concentrating fast.Mega-rounds($100M+)captured a record 60%of

4、 all capital across just 19 deals,as average deal size climbed to$29.6M,up 47%YoY.Eight new unicorns emerged in Q126 the highest single-quarter count since Q222.See the data+47%Jump in M&A activity QoQ.Digital health M&A surged to 56 deals in Q126,up from 38 in Q425,with buyers reserving premium val

5、uations for companies with strong commercial traction,not just regulatory approval.Abbotts$23B acquisition of Exact Sciences and DeepHealths$269M Gleamer deal underscore that regulatory clearance is table stakes,commercial scale drives price.See the data 23%Of quarterly funding wentto AI in drug dis

6、covery.Big pharma partnered with established discovery platforms to accelerate R&D timelines Earendil Labs raised$787M backed by Pfizer and Sanofi,while Takeda partnered with Iambic Therapeutics in a relationship worth up to$1.7B.Early-stage capital took a different bet:platforms engineering entirel